The Pyrazolo[3,4-<i>d</i>]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma
Si306, a pyrazolo[3,4-<i>d</i>]pyrimidine derivative recently identified as promising anticancer agent, has shown favorable in vitro and in vivo activity profile against neuroblastoma (NB) models by acting as a competitive inhibitor of c-Src tyrosine kinase. Nevertheless, Si306 antitumor...
Main Authors: | Enrico Rango, Fabio Pastorino, Chiara Brignole, Arianna Mancini, Federica Poggialini, Salvatore Di Maria, Claudio Zamperini, Giulia Iovenitti, Anna Lucia Fallacara, Samantha Sabetta, Letizia Clementi, Massimo Valoti, Silvia Schenone, Adriano Angelucci, Mirco Ponzoni, Elena Dreassi, Maurizio Botta |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/3/659 |
Similar Items
-
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-<i>d</i>]Pyrimidine Dual Src/P-Glycoprotein Inhibitor
by: Anna Lucia Fallacara, et al.
Published: (2019-06-01) -
Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2—An In Vitro Study
by: Lucyna Matusewicz, et al.
Published: (2018-11-01) -
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo
by: Marija Nešović, et al.
Published: (2020-06-01) -
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants
by: Nur Dini Fatini Mohammad Faizal, et al.
Published: (2023-11-01) -
DOPE/CHEMS-Based EGFR-Targeted Immunoliposomes for Docetaxel Delivery: Formulation Development, Physicochemical Characterization and Biological Evaluation on Prostate Cancer Cells
by: Thais da Silva Moreira, et al.
Published: (2023-03-01)